Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same

A compound, stereoisomers thereof or pharmaceutically acceptable salts thereof, wherein the sulfoximine compound is represented by formula I below:

• in above formula I,
• R1 is CF2H or CF3;
• L1 is —(C1-3 alkylene)-, —C(═O)—, —S(═O)2—, —S(═O)2—(C1-3 alkylene)-, —C(═O)N(Ra)—,
• Ra is H or C1-6 alkyl;
• Q1 and Q2 are each independently CH or N;
• a, b, c, d and k are each independently 1 or 2;
• {circle around (A)} is phenyl, benzyl, 5- to 12-membered heteroaryl including in a ring 1 to 3 heteroatoms independently selected from the group consisting of N, O and S,
• at least one H of above {circle around (A)} may be each independently substituted with C1-6 alkyl, C1-6 alkoxy, 3- to 12-membered heterocycloalkyl including in a ring 1 to 3 heteroatoms independently selected from the group consisting of N, O and S (in which at least one H of heterocycloalkyl may be substituted with —C(═O)(C1-6 alkyl), 5- to 12-membered heteroaryl including in a ring 1 to 3 heteroatoms independently selected from the group consisting of N, O and S, —CF3, —S(CF3), halogen or —S(═NH)(=O)Rc;
• Rc is H or C1-6 alkyl;
• {circle around (B)} is phenyl or 5- to 6-membered heteroaryl including in a ring 1 to 3 heteroatoms independently selected from the group consisting of N, and S;
• at least one H of above {circle around (B)} may be each independently substituted with C1-6 alkyl or halogen;
• {circle around (D)} is
• at least one H of above {circle around (D)} may be each independently substituted with C1-6 alkyl or halogen;
• Z is CH or N;
• m and n are each independently 0, or 1;
• p, q, r, s and t are 1;
• L2 is a single bond, —(C═O)—, —C(═O)O—, —C(═O)O—(C1-3 alkylene)- or —S(═O)2—;
• R2 is H, C1-6 alkyl, C6-C12 aryl, CF3 or —(P═O)(ORb)2;
• Rb is H or C1-6 alkyl;
• and
• R3 is C1-6 alkyl.